Trial Profile
Immunotherapy by Nivolumab After Prior Chemotherapy for HIV+ Patients With Advanced Non-small Cell Lung Cancer (NSCLC): IFCT-CHIVA2 Phase IIa Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 May 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Proof of concept; Therapeutic Use
- Acronyms CHIVA2
- 11 May 2023 Status changed from discontinued to completed.
- 01 Aug 2021 Status has been changed to discontinued, as per results published in the Lung Cancer
- 01 Aug 2021 Results published in the Lung Cancer